Recently, the purpurin analog R162 (an inhibitor of GLUD1) also showed promising results with respect to attenuating the proliferation of breast, NSCLC, and glioma cells in vitro and in patient-derived xenograft mouse models 23
Cold chain logistics keep your medicines safe, effective, and temperature-controlled
Among firms with 200 or more workers that cover GLP-1 agonists primarily for weight loss, 33% say that covering these medications for weight loss will have a significant impact on their prescription drug spending, 33% say that it will have a moderate impact, 20% say that it will have a minor impact, 3% say that it will have no impact, and 11% do not know what the impact will be [Figure 13.18]
Vitamin B12 injections should be used in accordance with professional guidance
Patients should discuss with their primary care physician and/or endocrinologist whether they should cease GLP-1 medication use in order to balance the risk of vision loss from NAION in the fellow eye with the hypoglycemic and cardiovascular benefits from treatment